Welcome to the THALOMID REMS® program
Important information about THALOMID® (thalidomide) and the THALOMID Risk Evaluation
and Mitigation Strategy (REMS) program
-
THALOMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with THALOMID provided adequate precautions are taken to avoid pregnancy
-
To avoid embryo-fetal exposure, THALOMID is only available under a restricted distribution program called "THALOMID REMS®"
-
Only prescribers and pharmacies certified by the THALOMID REMS® program can prescribe and dispense THALOMID to patients who are enrolled and meet all the conditions of the THALOMID REMS® program
The goals of the THALOMID risk evaluation and mitigation strategy are as follows:
-
To prevent the risk of embryo-fetal exposure to THALOMID
-
To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for THALOMID
For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
THALOMID® and THALOMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2021. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
